Antibody testing in peripheral nerve disorders

Handbook of Clinical Neurology

Volumn 115, Issue , 2013, Pages 189-212

  Steck, Andreas ^a   Yuki, Nobuhiro ^b   Graus, Francesc ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIBODY; DIAGNOSTIC AGENT; GANGLIOSIDE;

ANIMAL; ARTICLE; DYSIMMUNE; GUILLAIN-BARRÉ SYNDROME; HUMAN; IMMUNOLOGICAL TECHNIQUE; MAG; METABOLISM; METHODOLOGY; MOLECULAR MIMICRY; NEUROPATHY; ONCONEURAL; PERIPHERAL NEUROPATHY;

AUTOANTIBODY; DYSIMMUNE; GANGLIOSIDE; GUILLAIN-BARRÉ SYNDROME; MAG; MOLECULAR MIMICRY; NEUROPATHY; ONCONEURAL;

ANIMALS; ANTIBODIES; HUMANS; IMMUNOLOGIC TECHNIQUES; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84881502149     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52902-2.00011-4     Document Type: Chapter

References (202)

1. Adams D., Kuntzer T., Steck A.J., et al. Motor conduction block and high titres of anti-GM1 ganglioside antibodies: pathological evidence of a motor neuropathy in a patient with lower motor neuron syndrome. J Neurol Neurosurg Psychiatry 1993, 56:982-987.
2. Albert M.L., Austin L.M., Darnell R.B. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000, 47:9-17.
3. Antoine J.C., Mosnier J.F., Absi L., et al. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 1999, 67:7-14.
4. Antoine J.C., Honnorat J., Camdessanche J.P., et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001, 49:214-221.
5. Attarian S., Azulay J.P., Boucraut J., et al. Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies. Clin Neurophysiol 2001, 112:457-463.
6. Azulay J.P., Blin O., Pouget J., et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994, 44:429-432.
7. Bernal F., Graus F., Pifarre A., et al. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol (Berl) 2002, 103:509-515.
8. Bickerstaff E.R., Cloake P.C. Mesencephalitis and rhombencephalitis. Br Med J 1951, 2:77-81.
9. Bida J.P., Kyle R.A., Therneau T.M., et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009, 84:685-693.
10. Bollensen E., Schipper H.I., Steck A.J. Motor neuropathy with activity of monoclonal IgM antibody to GD1a ganglioside. J Neurol 1989, 236:353-355.
11. Briani C., Berger J.S., Latov N. Antibodies to chondroitin sulfate C: a new detection assay and correlations with neurological diseases. J Neuroimmunol 1998, 84:117-121.
12. Briani C., Santoro M., Latov N. Antibodies to chondroitin sulfates A, B, and C: clinico-pathological correlates in neurological diseases. J Neuroimmunol 2000, 108:216-220.
13. Briani C., Ruggero S., Alaedini A., et al. Anti-heparan sulfate antibodies in neurological disease. Muscle Nerve 2002, 26:713-715.
14. Brouet J.C., Mariette X., Gendron M.C., et al. Monoclonal IgM from patients with peripheral demyelinating neuropathies cross-react with bacterial polypeptides. Clin Exp Immunol 1994, 96:466-469.
15. Burger D., Simon M., Perruisseau G., et al. The epitope(s) recognized by HNK-1 antibody and IgM paraprotein in neuropathy is present on several N-linked oligosaccharide structures on human P0 and myelin-associated glycoprotein. J Neurochem 1990, 54:1569-1575.
16. Camdessanche J.P., Antoine J.C., Honnorat J., et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: a clinical and electrophysiological study of 20 patients. Brain 2002, 125:166-175.
17. Camdessanche J.P., Jousserand G., Ferraud K., et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009, 132:1723-1733.
18. Carpentier A.F., Rosenfeld M.R., Delattre J.Y., et al. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 1998, 4:2819-2824.
19. Carpo M., Pedotti R., Allaria S., et al. Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies. J Neurol Sci 1999, 168:78-84.
20. Caudie C., Vial C., Petiot P., et al. Monoclonal IgM autoantibody activity vis-a-vis glycoconjugates of peripheral nerves: apropos of 112 cases. Ann Biol Clin (Paris) 2001, 59:567-577.
21. Cavanna B., Carpo M., Pedotti R., et al. Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. J Neuroimmunol 1999, 94:157-164.
22. Chiba A., Kusunoki S., Shimizu T., et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992, 31:677-679.
23. Chiba A., Kusunoki S., Obata H., et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993, 43:1911-1917.
24. Chinn J.S., Schuffler M.D. Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 1988, 95:1279-1286.
25. Cocito D., Isoardo G., Ciaramitaro P., et al. Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody. Muscle Nerve 2001, 24:1278-1282.
26. Corbo M., Quattrini A., Lugaresi A., et al. Patterns of reactivity of human anti-GM1 antibodies with spinal cord and motor neurons. Ann Neurol 1992, 32:487-493.
27. Dabby R., Weimer L.H., Hays A.P., et al. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology 2000, 54:1448-1452.
28. Dalakas M.C., Quarles R.H. Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens?. Ann Neurol 1996, 39:419-422.
29. Darnell R.B., Posner J.B. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003, 349:1543-1554.
30. De Angelis M.V., Di Muzio A., Lupo S., et al. Anti-GD1a antibodies from an acute motor axonal neuropathy patient selectively bind to motor nerve fiber nodes of Ranvier. J Neuroimmunol 2001, 121:79-82.
31. De Giorgio R., Guerrini S., Barbara G., et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004, 126:1872-1883.
32. Eggers C., Hagel C., Pfeiffer G. Anti-Hu-associated paraneoplastic sensory neuropathy with peripheral nerve demyelination and microvasculitis. J Neurol Sci 1998, 155:178-181.
33. Ellie E., Vital A., Steck A., et al. Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases. J Neurol 1996, 243:34-43.
34. Erb S., Ferracin F., Fuhr P., et al. Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies. J Neurol 2000, 247:767-772.
35. Fagarasan S., Honjo T. T-Independent immune response: new aspects of B cell biology. Science 2000, 290:89-92.
36. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956, 255:57-65.
37. Fluri F., Ferracin F., Erne B., et al. Microheterogeneity of anti-myelin-associated glycoprotein antibodies. J Neurol Sci 2003, 207:43-49.
38. Freddo L., Yu R.K., Latov N., et al. Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology 1986, 36:454-458.
39. Fruttiger M., Montag D., Schachner M., et al. Crucial role for the myelin-associated glycoprotein in the maintenance of axon-myelin integrity. Eur J Neurosci 1995, 7:511-515.
40. Gabriel J.M., Erne B., Miescher G.C., et al. Selective loss of myelin-associated glycoprotein from myelin correlates with anti-MAG antibody titre in demyelinating paraproteinaemic polyneuropathy. Brain 1996, 119:775-787.
41. Gabriel J.M., Erne B., Bernasconi L., et al. Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy. Acta Neuropathol (Berl) 1998, 95:540-546.
42. Gong Y., Tagawa Y., Lunn M.P., et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002, 125:2491-2506.
43. Goodfellow J.A., Bowes T., Sheikh K., et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 2005, 25:1620-1628.
44. Govoni V., Granieri E., Manconi M., et al. Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy?: a population-based study in the Local Health District of Ferrara, Italy. J Neurol Sci 2003, 216:99-103.
45. Graus F., Elkon K.B., Lloberes P., et al. Neuronal antinuclear antibody (anti-Hu) in paraneoplastic encephalomyelitis simulating acute polyneuritis. Acta Neurol Scand 1987, 75:249-252.
46. Graus F., Illa I., Agusti M., et al. Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci 1991, 106:82-87.
47. Graus F., Bonaventura I., Uchuya M., et al. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology 1994, 44:2258-2261.
48. Graus F., Keime-Guibert F., Rene R., et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001, 124:1138-1148.
49. Graus F., Delattre J.Y., Antoine J.C., et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004, 75:1135-1140.
50. Graus F., Vincent A., Pozo-Rosich P., et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005, 165:166-171.
51. Graus F., Saiz A., Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010, 257:509-517.
52. Gure A.O., Stockert E., Scanlan M.J., et al. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 2000, 97:4198-4203.
53. Hadden R.D.M., Cornblath D.R., Hughes R.A.C., et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998, 44:780-788.
54. Hafer-Macko C., Hsieh S.T., Li C.Y., et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996, 40:635-644.
55. Hafer-Macko C.E., Sheikh K.A., Li C.Y., et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996, 39:625-635.
56. Hays A.P., Latov N., Takatsu M., et al. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology 1987, 37:242-256.
57. Hellqvist E., Kvarnstrom M., Soderberg A., et al. Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells. Haematologica 2010, 95:627-636.
58. Hiraga A., Kuwabara S., Ogawara K., et al. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome. Neurology 2005, 64:856-860.
59. Ho T.W., Mishu B., Li C.Y., et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995, 118:597-605.
60. Ho T.W., Willison H.J., Nachamkin I., et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999, 45:168-173.
61. Hoffmann L.A., Jarius S., Pellkofer H.L., et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008, 79:767-773.
62. Illa I., Ortiz N., Gallard E., et al. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 1995, 38:218-224.
63. Ilyas A.A., Quarles R.H., Dalakas M.C., et al. Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Ann Neurol 1985, 18:655-659.
64. Ilyas A.A., Li S.C., Chou D.K., et al. Gangliosides GM2, IV4GalNAcGM1b, and IV4GalNAcGC1a as antigens for monoclonal immunoglobulin M in neuropathy associated with gammopathy. J Biol Chem 1988, 263:4369-4373.
65. Ilyas A.A., Willison H.J., Dalakas M.C., et al. Identification and characterization of gangliosides reacting with IgM paraproteins in three patients with neuropathy associated with biclonal gammopathy. J Neurochem 1988, 51:851-858.
66. Ilyas A.A., Willison H.J., Quarles R.H., et al. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 1988, 23:440-447.
67. Ilyas A.A., Cook S.D., Dalakas M.C., et al. Anti-MAG IgM paraproteins from some patients with polyneuropathy associated with IgM paraproteinemia also react with sulfatide. J Neuroimmunol 1992, 37:85-92.
68. Isoardo G., Deaglio S., Cocito D., et al. Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells. J Neuroimmunol 2005, 161:78-86.
69. Ito M., Kuwabara S., Odaka M., et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008, 255:674-682.
70. Jacobs B.C., van Doorn P.A., Schmitz P.I.M., et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996, 40:181-187.
71. Jacobs B.C., Rothbarth P.H., van dar Meché F.G.A., et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998, 51:1110-1115.
72. Jacobs J.M., Scadding J.W. Morphological changes in IgM paraproteinaemic neuropathy. Acta Neuropathol (Berl) 1990, 80:77-84.
73. Joint Task Force of the EFNS and the PNS European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006, 11:1-8.
74. Kaku D.A., England J.D., Sumner A.J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994, 117:941-947.
75. Kaldor J., Speed B.R. Guillain-Barré syndrome and Campylobacter jejuni: a serological study. Br Med J (Clin Res Ed) 1984, 288:1867-1870.
76. Katz J.S., Saperstein D.S., Gronseth G., et al. Distal acquired demyelinating symmetric neuropathy. Neurology 2000, 54:615-620.
77. Kelly J.J., Kyle R.A., Miles J.M., et al. The spectrum of peripheral neuropathy in myeloma. Neurology 1981, 31:24-31.
78. Khwaja S., Sripathi N., Ahmad B.K., et al. Paraneoplastic motor neuron disease with type 1 Purkinje cell antibodies. Muscle Nerve 1998, 21:943-945.
79. Kimoto K., Koga M., Odaka M., et al. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 2006, 67:1837-1843.
80. King R.H., Thomas P.K. The occurrence and significance of myelin with unusually large periodicity. Acta Neuropathol (Berl) 1984, 63:319-329.
81. Kinsella L.J., Lange D.J., Trojaborg W., et al. Clinical and electrophysiologic correlates of elevated anti-GM1 antibody titers. Neurology 1994, 44:1278-1282.
82. Koga M., Yoshino H., Morimatsu M., et al. Anti-GT1a IgG in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2002, 72:767-771.
83. Koga M., Takahashi M., Masuda M., et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Neurology 2005, 65:1376-1381.
84. Kuijf M.L., Eurelings M., Tio-Gillen A.P., et al. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 2009, 73:688-695.
85. Kulling D., Reed C.E., Verne G.N., et al. Intestinal pseudo-obstruction as a paraneoplastic manifestation of malignant thymoma. Am J Gastroenterol 1997, 92:1564-1566.
86. Kusunoki S., Chiba A., Kon K., et al. N-Acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 1994, 35:570-576.
87. Kusunoki S., Iwamori M., Chiba A., et al. GM1b is a new member of antigen for serum antibody in Guillain-Barré syndrome. Neurology 1996, 47:237-242.
88. Kusunoki S., Chiba A., Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 1999, 22:1071-1074.
89. Kuwabara S., Ogawara K., Misawa S., et al. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barré syndrome?. Neurology 2004, 63:529-533.
90. Kyle R.A., Garton J.P. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987, 62:719-731.
91. Latov N., Godfrey M., Thomas Y., et al. Neuropathy and anti-myelin-associated glycoprotein IgM M proteins: T cell regulation of M protein secretion in vitro. Ann Neurol 1985, 18:182-188.
92. Lee K.W., Inghirami G., Spatz L., et al. The B-cells that express anti-MAG antibodies in neuropathy and non-malignant IgM monoclonal gammopathy belong to the CD5 subpopulation. J Neuroimmunol 1991, 31:83-88.
93. Leger J.M., Behin A. Multifocal motor neuropathy. Curr Opin Neurol 2005, 18:567-573.
94. Lisak R.P., Mitchell M., Zweiman B., et al. Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies. Ann Neurol 1977, 1:72-78.
95. Liu J.X., Willison H.J., Pedrosa-Domellof F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009, 50:3226-3232.
96. Lombardi R., Erne B., Lauria G., et al. IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Ann Neurol 2005, 57:180-187.
97. Lopate G., Kornberg A.J., Yue J., et al. Anti-myelin associated glycoprotein antibodies: variability in patterns of IgM binding to peripheral nerve. J Neurol Sci 2001, 188:67-72.
98. Lopate G., Choksi R., Pestronk A. Severe sensory ataxia and demyelinating polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies. Muscle Nerve 2002, 25:828-836.
99. Lunn M.P., Crawford T.O., Hughes R.A., et al. Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain 2002, 125:904-911.
100. Mendell J.R., Sahenk Z., Whitaker J.N., et al. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol 1985, 17:243-254.
101. Mizutani K., Oka N., Kusunoki S., et al. Sensorimotor demyelinating neuropathy with IgM antibody against gangliosides GD1a, GT1b and GM3. J Neurol Sci 2001, 188:9-11.
102. Molinuevo J.L., Graus F., Serrano C., et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998, 44:976-980.
103. Monaco S., Ferrari S., Bonetti B., et al. Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex. J Neuropathol Exp Neurol 1995, 54:96-104.
104. Mori M., Kuwabara S., Fukutake T., et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001, 56:1104-1106.
105. Nagashima T., Koga M., Odaka M., et al. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol 2007, 64:1519-1523.
106. Nakao T., Kon K., Ando S., et al. Novel lacto-ganglio type gangliosides with GM2-epitope in bovine brain which react with IgM from a patient of the amyotrophic lateral sclerosis-like disorder. J Biol Chem 1993, 268:21028-21034.
107. Nardelli E., Steck A.J., Barkas T., et al. Motor neuron syndrome and monoclonal IgM with antibody activity against gangliosides GM1 and GD1b. Ann Neurol 1988, 23:524-528.
108. Nardelli E., Bassi A., Mazzi G., et al. Systemic passive transfer studies using IgM monoclonal antibodies to sulfatide. J Neuroimmunol 1995, 63:29-37.
109. Nobile-Orazio E., Latov N., Hays A.P., et al. Neuropathy and anti-MAG antibodies without detectable serum M-protein. Neurology 1984, 34:218-221.
110. Nobile-Orazio E., Barbieri S., Baldini L., et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand 1992, 85:383-390.
111. Nobile-Orazio E., Carpo M., Meucci N., et al. Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies. J Neurol Sci 1992, 109:200-206.
112. Nobile-Orazio E., Manfredini E., Carpo M., et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994, 36:416-424.
113. Nobile-Orazio E., Cappellari A., Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005, 31:663-680.
114. Nobile-Orazio E., Gallia F., Terenghi F., et al. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies?. J Neurol Sci 2008, 266:156-163.
115. Notturno F., Caporale C.M., Uncini A. Acute sensory ataxic neuropathy with antibodies to GD1b and GQ1b gangliosides and prompt recovery. Muscle Nerve 2008, 37:265-268.
116. O'Hanlon G.M., Veitch J., Gallardo E., et al. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity 2000, 32:133-144.
117. O'Leary C.P., Willison H.J. Autoimmune ataxic neuropathies (sensory ganglionopathies). Curr Opin Neurol 1997, 10:366-370.
118. O'Leary C.P., Veitch J., Durward W.F., et al. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry 1996, 61:649-651.
119. O'Neill J.H., Murray N.M., Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988, 111:577-596.
120. Odaka M., Yuki N., Yamada M., et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003, 126:2279-2290.
121. Oga T., Kusunoki S., Fujimura H., et al. Severe motor-dominant neuropathy with IgM M-protein binding to the NeuAcα2-3Galβ- moiety. J Neurol Sci 1998, 154:4-7.
122. Ogawa-Goto K., Funamoto N., Ohta Y., et al. Myelin gangliosides of human peripheral nervous system: an enrichment of GM1 in the motor nerve myelin isolated from cauda equina. J Neurochem 1992, 59:1844-1849.
123. Ogawara K., Kuwabara S., Mori M., et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000, 48:624-631.
124. Ogawara K., Kuwabara S., Koga M., et al. Anti-GM1b IgG antibody is associated with acute motor axonal neuropathy and Campylobacter jejuni infection. J Neurol Sci 2003, 210:41-45.
125. Ogino M., Tatum A.H., Latov N. Affinity studies of human anti-MAG antibodies in neuropathy. J Neuroimmunol 1994, 52:41-46.
126. Oh S.J., Slaughter R., Harrell L. Paraneoplastic vasculitic neuropathy: a treatable neuropathy. Muscle Nerve 1991, 14:152-156.
127. Oka N., Kusaka H., Kusunoki S., et al. IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons. Muscle Nerve 1996, 19:528-530.
128. Oki Y., Koike H., Iijima M., et al. Ataxic vs painful form of paraneoplastic neuropathy. Neurology 2007, 69:564-572.
129. Olney R.K., Lewis R.A., Putnam T.D., et al. Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 2003, 27:117-121.
130. Ortiz N., Rosa R., Gallardo E., et al. IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release. J Neuroimmunol 2001, 119:114-123.
131. Pestronk A. Testing for serum IgM binding to GM1 ganglioside in clinical practice. Neurology 2000, 54:2353-2354.
132. Pestronk A., Cornblath D.R., Ilyas A.A., et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988, 24:73-78.
133. Pestronk A., Li F., Griffin J., et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 1991, 41:357-362.
134. Phongsisay V., Susuki K., Matsuno K., et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome. J Neuroimmunol 2008, 205:101-104.
135. Qin Z., Guan Y. Experimental polyneuropathy produced in guinea-pigs immunized against sulfatide. Neuroreport 1997, 8:2867-2870.
136. Quattrini A., Corbo M., Dhaliwal S.K., et al. Anti-sulfatide antibodies in neurological disease: binding to rat dorsal root ganglia neurons. J Neurol Sci 1992, 112:152-159.
137. Rees J.H., Gregson N.A., Hughes R.A.C. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995, 38:809-816.
138. Rees J.H., Soudain S.E., Gregson N.A., et al. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995, 333:1374-1379.
139. Renaud S., Steck A., Latov N. Neuropathies associated with monoclonal gammopathy. Clinical Neuroimmunology 2005, 327-337. Oxford University Press, Oxford. 2nd edn. J. Antel, G. Birnbaum, H.P. Hartung, A. Vincent (Eds.).
140. Richter R.B. The ataxic form of polyradiculoneuritis (Landry-Guillain-Barré syndrome): clinical and pathologic observations. J Neuropathol Exp Neurol 1962, 21:171-184.
141. Roberts W.K., Deluca I.J., Thomas A., et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009, 119:2042-2051.
142. Romorini A., Frediani F., Rapuzzi S., et al. Anti-Ri antibodies and peripheral neuropathy in a man without malignancy. Eur Neurol 2004, 51:177-178.
143. Ropper A.H. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986, 43:1150-1152.
144. Rosoklija G.B., Dwork A.J., Younger D.S., et al. Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol (Berl) 2000, 99:55-62.
145. Rudnicki S.A., Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 2005, 18:598-603.
146. Sabater L., Titulaer M., Saiz A., et al. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008, 70:924-928.
147. Sadiq S.A., Thomas F.P., Kilidireas K., et al. The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology 1990, 40:1067-1072.
148. Saiz A., Dalmau J., Butler M.H., et al. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 1999, 66:214-217.
149. Salazar-Grueso E.F., Routbort M.J., Martin J., et al. Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants. Ann Neurol 1990, 27:558-563.
150. Santoro M., Uncini A., Corbo M., et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 1992, 31:385-390.
151. Schönhöfer P.S. Guillain-Barré syndrome and parenteral gangliosides. Lancet 1991, 338:757.
152. Sheikh K.A., Deerinck T.J., Ellisman M.H., et al. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999, 122:449-460.
153. Sherman W.H., Latov N., Hays A.P., et al. Monoclonal IgM kappa antibody precipitating with chondroitin sulfate C from patients with axonal polyneuropathy and epidermolysis. Neurology 1983, 33:192-201.
154. Sommer C., Weishaupt A., Brinkhoff J., et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005, 365:1406-1411.
155. Spatz L.A., Williams M., Brender B., et al. DNA sequence analysis and comparison of the variable heavy and light chain regions of two IgM, monoclonal, anti-myelin associated glycoprotein antibodies. J Neuroimmunol 1992, 36:29-39.
156. Stalder A.K., Erne B., Reimann R., et al. Immunoglobulin M deposition in cutaneous nerves of anti-myelin-associated glycoprotein polyneuropathy patients correlates with axonal degeneration. J Neuropathol Exp Neurol 2009, 68:148-158.
157. Steck A.J., Murray N., Meier C., et al. Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology 1983, 33:19-23.
158. Steck A.J., Erne B., Gabriel J.M., et al. Paraproteinaemic neuropathies. Brain Pathol 1999, 9:361-368.
159. Steck A.J., Stalder A.K., Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol 2006, 19:458-463.
160. Stich O., Jarius S., Kleer B., et al. Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes. J Neuroimmunol 2007, 183:220-224.
161. Storstein A., Vedeler C. Neuropathy and malignancy: a retrospective survey. J Neurol 2001, 248:322-327.
162. Suzuki M., Suetake K., Kasama T., et al. Characterization of a phospholipid antigen reacting with serum antibody in patients with peripheral neuropathies and paraproteinemia. J Neurochem 2001, 79:970-975.
163. Susuki K., Rasband M.N., Tohyama K., et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007, 27:3956-3967.
164. +currents in isolated rat myelinated nerve fibers. Ann Neurol 1995, 37:436-442.
165. Tatsumoto M., Odaka M., Hirata K., et al. Isolated abducens nerve palsy as a regional variant of Guillain-Barré syndrome. J Neurol Sci 2006, 243:35-38.
166. Tatum A.H. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol 1993, 33:502-506.
167. Thomas F.P., Trojaborg W., Nagy C., et al. Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier. Acta Neuropathol (Berl) 1991, 82:378-383.
168. Titulaer M.J., Wirtz P.W., Willems L.N., et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008, 26:4276-4281.
169. Titulaer M.J., Klooster R., Potman M., et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009, 27:4260-4267.
170. Trojaborg W., Hays A.P., Van Den Berg L., et al. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve 1995, 18:730-735.
171. Van den Berg L.H., Lankamp C.L., De Jager A.E., et al. Anti-sulphatide antibodies in peripheral neuropathy. J Neurol Neurosurg Psychiatry 1993, 56:1164-1168.
172. Van den Berg L., Hays A.P., Nobile-Orazio E., et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve 1996, 19:637-643.
173. Vardhini D., Suneetha S., Ahmed N., et al. Comparative proteomics of the Mycobacterium leprae binding protein myelin P0: its implication in leprosy and other neurodegenerative diseases. Infect Genet Evol 2004, 4:21-28.
174. Vera J., Fenutria R., Canadas O., et al. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci U S A 2009, 106:1506-1511.
175. Vernino S., Wolfe G.I. Antibody testing in peripheral neuropathies. Neurol Clin 2007, 25:29-46.
176. Viallard J.F., Vincent A., Moreau J.F., et al. Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol 2005, 53:60-63.
177. Vital A., Vital C., Julien J., et al. Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol (Berl) 1989, 79:160-167.
178. Vital C., Vital A., Julien J., et al. Peripheral neuropathies and lymphoma without monoclonal gammopathy: a new classification. J Neurol 1990, 237:177-185.
179. Vital C., Vital A., Deminiere C., et al. Myelin modifications in 8 cases of peripheral neuropathy with Waldenstrom's macroglobulinemia and anti-MAG activity. Ultrastruct Pathol 1997, 21:509-516.
180. Waragai M., Chiba A., Uchibori A., et al. Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry 2006, 77:111-113.
181. Weiss M.D., Dalakas M.C., Lauter C.J., et al. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J Neuroimmunol 1999, 95:174-184.
182. Willison H.J., O'leary C.P., Veitch J., et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001, 124:1968-1977.
183. Wirguin I., Suturkova-Milosevic L., Della-Latta P., et al. Monoclonal IgM antibodies to GM1 and asialo-GM1 in chronic neuropathies cross-react with Campylobacter jejuni lipopolysaccharides. Ann Neurol 1994, 35:698-703.
184. Younger D.S., Dalmau J., Inghirami G., et al. Anti-Hu-associated peripheral nerve and muscle microvasculitis. Neurology 1994, 44:181-183.
185. Yu Z., Kryzer T.J., Griesmann G.E., et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001, 49:146-154.
186. Yuki N., Yoshino H., Sato S., et al. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990, 40:1900-1902.
187. Yuki N., Sato S., Miyatake T., et al. Motoneuron-disease-like disorder after ganglioside therapy. Lancet 1991, 337:1109-1110.
188. Yuki N., Yoshino H., Sato S., et al. Severe acute axonal form of Guillain-Barré syndrome associated with IgG anti-GD1a antibodies. Muscle Nerve 1992, 15:899-903.
189. Yuki N., Sato S., Tsuji S., et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993, 118:83-87.
190. Yuki N., Sato S., Tsuji S., et al. Frequent presence of anti-GQ1b antibody in Fisher's syndrome. Neurology 1993, 43:414-417.
191. Yuki N., Taki T., Inagaki F., et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 1993, 178:1771-1775.
192. Yuki N., Yamada M., Sato S., et al. Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome. Muscle Nerve 1993, 16:642-647.
193. Yuki N. Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody. Ann Neurol 1996, 39:668-672.
194. Yuki N., Taki T., Handa S. Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J Neuroimmunol 1996, 71:155-161.
195. Yuki N., Tagawa Y., Irie F., et al. Close association of Guillain-Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1α. J Neuroimmunol 1997, 74:30-34.
196. Yuki N., Ho T.W., Tagawa Y., et al. Autoantibodies to GM1b and GalNAc-GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China. J Neurol Sci 1999, 164(2):134-138.
197. Yuki N., Ang C.W., Koga M., et al. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 2000, 47:314-321.
198. Yuki N., Susuki K., Hirata K. Ataxic form of Guillain-Barré syndrome associated with anti-GD1b IgG antibody. J Neurol Neurosurg Psychiatry 2000, 69:136-137.
199. Yuki N., Susuki K., Hirata K. Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: relation to Miller Fisher syndrome. Neurology 2000, 54:1851-1853.
200. Yuki N., Odaka M., Hirata K. Acute ophthalmoparesis (without ataxia) associated with anti-GQ1b IgG antibody: clinical features. Ophthalmology 2001, 108:196-200.
201. Yuki N., Yamada M., Koga M., et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001, 49:712-720.
202. Yuki N., Susuki K., Koga M., et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain- Barré syndrome. Proc Natl Acad Sci U S A 2004, 101:11404-11409.